Paper41798535
Anaplastic Lymphoma Kinase (ALK)-Positive Large B-cell Lymphoma in Children: A Case Report and Review of Literature.
Dananjaya R and 6 others. Cureus, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Anaplastic Lymphoma Kinase (ALK)-Positive Large B-cell Lymphoma in Children: A Case Report and Review of Literature. Papers, record 41798535. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41798535
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Anaplastic Lymphoma Kinase (ALK)-Positive Large B-cell Lymphoma in Children: A Case Report and Review of Literature.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References43
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27740969 | ALK-positive Large B-cell Lymphoma: A Clinicopathologic Study of 26 Cases With Review of Additional 108 Cases in the Literature. | Am J Surg Pathol | 2017 | https://conductscience.org/library/papers/27740969 | PubMed |
| 2 | 34141790 | Diagnosis and treatment of pediatric anaplastic lymphoma kinase-positive large B-cell lymphoma: A case report. | World J Clin Cases | 2021 | https://conductscience.org/library/papers/34141790 | PubMed |
| 3 | 28665943 | Anaplastic lymphoma kinase-positive large B-cell lymphoma: Clinico-pathological study of 17 cases with review of literature. | PLoS One | 2017 | https://conductscience.org/library/papers/28665943 | PubMed |
| 4 | 33261174 | Hodgkin Reed-Sternberg-Like Cells in Non-Hodgkin Lymphoma. | Diagnostics (Basel) | 2020 | https://conductscience.org/library/papers/33261174 | PubMed |
| 5 | 35802834 | Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. | Blood | 2022 | https://conductscience.org/library/papers/35802834 | PubMed |
| 6 | 39906668 | Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review. | Front Oncol | 2024 | https://conductscience.org/library/papers/39906668 | PubMed |
| 7 | 34151703 | Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK + LBCL): a systematic review of clinicopathological features and management. | Leuk Lymphoma | 2021 | https://conductscience.org/library/papers/34151703 | PubMed |
| 8 | 8122112 | Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. | Science | 1994 | https://conductscience.org/library/papers/8122112 | PubMed |
| 9 | 26781614 | ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern. | Int J Hematol | 2016 | https://conductscience.org/library/papers/26781614 | PubMed |
| 10 | 38573563 | ALK-positive large B-cell lymphoma (ALK + LBCL) with aberrant CD3 expression. | J Hematop | 2024 | https://conductscience.org/library/papers/38573563 | PubMed |
| 11 | 35732829 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. | Leukemia | 2022 | https://conductscience.org/library/papers/35732829 | PubMed |
| 12 | 37935098 | NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. | J Natl Compr Canc Netw | 2023 | https://conductscience.org/library/papers/37935098 | PubMed |
| 13 | 29455642 | Role and targeting of anaplastic lymphoma kinase in cancer. | Mol Cancer | 2018 | https://conductscience.org/library/papers/29455642 | PubMed |
| 14 | 26418745 | FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase. | Elife | 2015 | https://conductscience.org/library/papers/26418745 | PubMed |
| 15 | 26630010 | Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactions. | Proc Natl Acad Sci U S A | 2015 | https://conductscience.org/library/papers/26630010 | PubMed |
| 16 | 37773318 | ALK fusions in the pan-cancer setting: another tumor-agnostic target? | NPJ Precis Oncol | 2023 | https://conductscience.org/library/papers/37773318 | PubMed |
| 17 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 18 | 37333805 | The epidemiological patterns of non-Hodgkin lymphoma: global estimates of disease burden, risk factors, and temporal trends. | Front Oncol | 2023 | https://conductscience.org/library/papers/37333805 | PubMed |
| 19 | 36943241 | Current Approach to Undifferentiated Neoplasms, With Focus on New Developments and Novel Immunohistochemical Stains. | Arch Pathol Lab Med | 2023 | https://conductscience.org/library/papers/36943241 | PubMed |
| 20 | 22474449 | Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma. | Adv Hematol | 2012 | https://conductscience.org/library/papers/22474449 | PubMed |
Genes43
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41798535
GET https://conductscience.org/api/papers/v1/41798535/references?page=2